Moshe Kupferstein Medicine PC
Moshe Kupferstein Medicine PC was paid $1.35M by Medicaid between Apr 2021 and Aug 2023, across 19 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 65% of everything it billed.
BROOKLYN, NY 11219
Next to other Urgent Care Clinic/Center providers in New York
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 32,572 | $1.26M | |
| 2022 | 2,302 | $73K | |
| 2023 | 754 | $26K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 65% | 10,480 | 3,415 | $884K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 19% | 10,502 | 3,432 | $254K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 6.0% | 11,154 | 3,975 | $82K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.5% | 931 | 918 | $48K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.5% | 266 | 261 | $20K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.1% | 348 | 318 | $14K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 95 | 94 | $13K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 368 | 357 | $13K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 343 | 296 | $11K |
| 87428 | <1% | 85 | 74 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 154 | 148 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 669 | 637 | $2K |
7 more codes
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 38 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 16 | $723.68 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 30 | $521.17 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 102 | $414.94 |
| 99051 | <1% | 20 | $68.60 | |
| 87081 | <1% | 12 | $55.80 | |
| S9083 | Global fee urgent care centers | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.